Results: Of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium

BJU International

Volumn 105, Issue 3, 2010, Pages 317-321

  Petrylak, Daniel P ^a   Tangen, Catherine M ^b   Van Veldhuizen Jr , Peter J ^c   Goodwin, J Wendall ^d   Twardowski, Przemyslaw W ^e   Atkins, James N ^f   Kakhil, Shaker R ^g   Lange, Marianne K ^h   Mansukhani, Mahesh ⁱ   Crawford, E David ^j  

^a Columbia University ^*  (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Ozarks Regional CCOP   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f Southeast Cancer Control Consortium   (United States)

^g WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

^h Grand Rapids CCOP   (United States)

ⁱ Department of Medicine   (United States)

^j UNIVERSITY OF COLORADO   (United States)

more..

Author keywords

Chemotherapy resistant; Transitional cell carcinoma; ZD1839

Indexed keywords

CARBOPLATIN; GEFITINIB; PACLITAXEL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLADDER CARCINOMA; BRAIN ISCHEMIA; BRAIN TOXICITY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE COURSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY PELVIS CARCINOMA; LUNG TOXICITY; MALE; METASTASIS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION; TREATMENT RESPONSE; URETER CARCINOMA; URETHRA CARCINOMA;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; QUINAZOLINES; TREATMENT OUTCOME; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 75149171017     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08799.x     Document Type: Article

References (16)

1. Saxman SB, Propert KJ, Einhorn LH et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997 15: 2564 2569
2. von der Maase H, Sengelov L, Roberts JT et al. Long-term survival Results: of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005 23: 4602 4608
3. McCaffrey JA, Hilton S, Mazumdar M et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 1997 15: 1853 1857 (Pubitemid 27209514)
4. Galsky MD, Mironov S, Iasonos A, Scattergood J, Boyle MG, Bajorin DF. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs 2007 25: 265 270
5. Gallucci M, Merola R, Leonardo C, Ruggeri EM, Cianciulli AM. Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU Int 2005 96: 440
6. Rochester MA, Patel N, Turney BW et al. The type 1 insulin-like growth factor receptor is over-expressed in bladder cancer. BJU Int 2007 100: 1396 1401
7. De Boer WI, Houtsmuller AB, Izadifar V, Muscatelli-Groux B, Van der Kwast TH, Chopin DK. Expression and functions of EGF, FGF and TGFbeta-growth-factor family members and their receptors in invasive human transitional-cell-carcinoma cells. Int J Cancer 1997 71: 284 291 (Pubitemid 27253003)
8. Bue P, Wester K, Sjostrom A et al. Expression of epidermal growth factor receptor in urinary bladder cancer metastases. Int J Cancer 1998 76: 189 193
9. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003 21: 2237 2246
10. Nutt JE, Lazarowicz HP, Mellon JK, Lunec J. Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2. Br J Cancer 2004 90: 1679 1685
11. Shrader M, Pino MS, Brown G et al. Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Mol Cancer Ther 2007 6: 277 85
12. Wülfing C, Machiels J, Richel D et al. A single arm, multicenter, open label, ph II study of lapatinib as 2L treatment of pts with locally advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract. ASCO Annual Meeting Proceedings. J Clin Oncol 2005 23 (16S 4594
13. Philips G, Sanford B, Halabi S, Bajorin D, Small EJ. Phase II study of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial carcinoma (UC): analysis of the second cohort of CALGB 90102. ASCO Annual Meeting Proceedings. J Clin Oncol 2006 24 (18S 4758
14. Perez-Soler R. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 2006 8 (Suppl. 1 S7 14
15. Blehm KN, Spiess PE, Bondaruk JE et al. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res 2006 12: 4671 4677
16. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008 359: 1757 1765